Showing 1 to 10 of 19
| Title | Consultation | Type | Consultation end date | Sort date |
|---|---|---|---|---|
| Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501] | Appraisal consultation | Technology appraisal guidance | Type:28 July 2021 | 20210728 |
| Berotralstat for preventing acute attacks of hereditary angioedema [ID1624] | Appraisal consultation | Technology appraisal guidance | Type:28 July 2021 | 20210728 |
| Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696] | Appraisal consultation | Technology appraisal guidance | Type:29 July 2021 | 20210729 |
| Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928] | Appraisal consultation | Technology appraisal guidance | Type:30 July 2021 | 20210730 |
| OTL-200 for treating metachromatic leukodystrophy [ID1666] | Evaluation consultation | Highly specialised technology | Type:30 July 2021 | 20210730 |
| Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892] | Appraisal consultation | Technology appraisal guidance | Type:02 August 2021 | 20210802 |
| Metastatic spinal cord compression in adults: risk assessment, diagnosis and management | Draft scope consultation | NICE guideline | Type:02 August 2021 | 20210802 |
| Belimumab for treating lupus nephritis [ID2722] | Appraisal consultation | Technology appraisal guidance | Type:03 August 2021 | 20210803 |
| SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea | Diagnostics consultation | Diagnostics guidance | Type:04 August 2021 | 20210804 |
| Tobacco: preventing uptake, promoting quitting and treating dependence (update) | Draft guidance consultation | NICE guideline | Type:06 August 2021 | 20210806 |